ArticleScientific reports2025
Analysis of clinical features and SS-OCT findings in patients with focal choroidal excavation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Application of Microscope-Integrated 400 kHz Swept-Source Intraoperative OCT in Ophthalmic Surgery.Journal of clinical medicine · 2026Article
- Selective retina therapy for central serous chorioretinopathy with focal choroidal excavation: a retrospective case series of six eyes.International journal of retina and vitreous · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To analyze the epidemiology, clinical features, and Swept-Source Optical Coherence Tomography findings in patients with Focal Choroidal Excavation. 97 patients with FCE were identified from 50,000 scans of 25,000 individuals who underwent SS-OCT examinations. These patients' clinical and imaging features were recorded, while data from 37 individuals with follow-up records were analyzed. FCE lesions were classified into three subtypes: (1) type 1: leptochoroid type (SFCT: <100 μm), (2) type 2: normochoroid type (SFCT: 100-200 μm), and (3) type 3: pachychoroid type (SFCT: >200 μm). A total of 108 FCEs were identified in 100 eyes, with 66 (61.1%) classified as Conforming type and 42 (38.9%) as non-conforming type. The maximum depth of FCEs in the study cohort was 96.6 ± 78.4 μm, the maximum width was 875.1 ± 960.1 μm, and choroidal thickness under FCE was 200.5 ± 191.5 μm. We observed 10 chorioretinopathy coexisting with FCE and categorized FCE based on choroidal thickness, highlighting three distinct types associated with different chorioretinopathy. Follow-up assessments revealed the relative stability of FCE and the efficacy of Anti-VEGF treatment for FCE-related CNV. Choroidal thickness playing a role in determining the specific type of FCE when combined with chorioretinopathy. Factors such as choroidal inflammation, scarring, and abnormal dilation of choroidal blood vessels may contribute to the damage or loss of outer retinal and inner choroidal tissues in FCE cases. FCE typically demonstrates stability over time, and Anti-VEGF treatment has shown efficacy in managing FCE-related CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.